Shanghai TheraMabs Bio-technology co., LTD
We are professional supplier in antibodies and fusion proteins,such as Pembrolizumab, Nivolumab, Transtuzumab,etc.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Purchase
Description
PRALUENT (Alirocumab) is a human monoclonal antibody (IgG1 isotype) that targets proprotein convertase subtilisin kexin type 9 (PCSK9). Alirocumab is a PCSK9 inhibitor produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Alirocumab consists of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a human kappa light chain. A single Nlinked glycosylation site is located in each heavy chain within the CH2 domain of the Fc constant region of the molecule. The variable domains of the heavy and light chains combine to form the PCSK9 binding site within the antibody. Alirocumab has an approximate molecular weight of 146 kDa.
Alirocumab is supplied at a concentration of 150 mg/mL as a sterile, preservative-free, clear, colorless to pale yellow solution, which contains 6 mM histidine, 0.1 mg/mL polysorbate 20, 100 mg/mL sucrose, and Water for Injection, to pH 6.0.
Properties
Name | Alirocumab |
CAS NO. | 1245916-14-6 |
Type | Whole antibody |
Source | Human |
Target | PCSK9 |
Clone | Monoclone |
Molecular Weight | 146 kDa |
Formula | C6472H9996N1736O2032S42 |
Antibody Form | Purified immunoglobulin |
Physical Form | Solution |
Grade Standard | Medicine Grade |
Place of Origin | China (Mainland) |
Storage | -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light. |
Supply Ability
20 kilogram per year, 1 Gram（Min. Order）.
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
If you need more information, please contact us.
Detail information about the product please refer the website below:
https://en.wikipedia.org/wiki/Alirocumab
